West Pharmaceutical Services (WST US)
WST US$403.64
20 minute delayed
14 days free access
Join Market Matters and get full access to all our Opinion + Action
Performance
Advanced charting functionality with the ability to amend timeframes, chart type & indicator selection, powered by TradingView.
Share price activity
Displays share price activity. Volume = number of shares traded, Turnover = value of shares traded, VWAP = volume-weighted average price for the day, sourced from Morningstar.
- Last (Price)
- 403.64
- Change
- ▲ 5.35 (1.34)
- Bid / Ask
- 0.00 - 0.00
- Volume
- 172,713
- Turnover
- 56,567,460
- Open
- 396.95
- Day Range
- 396.95 - 404.90
- VWAP
- 403.14
- Prev Close
- 398.29
- Last Trade
- 28/10 4:10pm
Key information
Displays key information on the security, sourced from Morningstar.
- Sector
- Healthcare
- Shares Issued
- 70,375,762
- NTA/Share
- 42.45
- Last Dividend
- 0.22
- Dividend Ex Date
- 29 JUL 2026
- Dividend Pay Date
- 5 AUG 2026
Current (USD) · FY2025
Displays key financial data for the most recent fiscal year, in millions. Note - Per share data is in local currency terms irrespective of reporting currency, and may be different to the stated currency, sourced from Morningstar.
- Revenue
- 3,074.10
- EBITDA
- 755.30
- Profit
- 493.70
- Earnings Per Share (EPS)
- 6.79
- Dividend Per Share (DPS)
- 0.86
- Yield %
- 0.22
- Market Cap
- 28,406.47
- Price to Earnings Ratio (P/E)
- 51.68
Estimates (USD) · FY2027
Displays consensus analyst’s estimates for key measures for the next fiscal year, sourced from Morningstar.
- Revenue
- 3,633.50
- EBITDA
- 1,071.00
- Profit
- 707.15
- Earnings Per Share (EPS)
- 9.73
- Dividend Per Share (DPS)
- 1.46
Quantitative rating
Displays Morningstar’s Quantitative Equity Research Rating for the security: a star rating from 1 (overvalued) to 5 (undervalued) from the share price against a fair value estimated by a statistical model of Morningstar’s analyst ratings, with the model’s economic moat, financial health and fair value uncertainty, sourced from Morningstar.
Overvalued
- Economic Moat
- Wide
- Financial Health
- Strong
- Uncertainty
- High
Morningstar Quantitative Rating as of 21 OCT 2026.
Quantitative Equity Rating Methodology – view here
Fair value estimate
Displays Morningstar’s quantitative fair value estimate for the security against the current share price, with the band around it: the five-star price below which the model would rate the stock five stars and the one-star price above which it would rate it one star, sourced from Morningstar.
Five-star price 294.86 Fair value 345.69 One-star price 405.28
Morningstar Quantitative Rating as of 21 OCT 2026.
Quantitative valuation
Displays where the share price sits in Morningstar’s quantitative fair value band, from the five-star price (undervalued) to the one-star price (overvalued), with the fair value estimate, the price to fair value ratio, the model’s valuation label and its uncertainty rating, sourced from Morningstar.
Buy
Sell
- Fair Value
- 345.69
- Price / Fair Value
- 1.14
- Valuation
- Overvalued
- Uncertainty
- High
Morningstar Quantitative Rating as of 21 OCT 2026. The slider runs from the five-star price (294.86) to the one-star price (405.28).
Displays useful ratios for the security, NB the pricing date used, sourced from Morningstar.
| Ratios |
|---|
| Currency (Price/reporting): USD/USD |
| Exchange Rate: 1.0000 |
Price, volume and trading statistics for the security, sourced from Morningstar.
| Price - closing or last bid | 393.48 |
| Price - 12 month high | 395.72 |
| Price - 12 month low | 223.84 |
| Pricing date | 20 OCT 2026 |
| Volume - avg. trading volume for the last ten days | 0.44 |
| Market capitalization | 27,691.45 |
| 12 Month High price date | 21 OCT 2026 |
| 12 Month Low price date | 30 JAN 2026 |
| Volume - avg. trading volume for the last 3 months | 0.61 |
| Price - 1 Day % Change | 1.21% |
| Price - 13 week price percent change | 9.53% |
| Price - 26 week price percent change | 43.23% |
| Price - 5 Day % Change | 5.03% |
| Price - 52 week price percent change | 40.84% |
| Price - YTD price percent change | 42.12% |
| Price % Change Month To Date | 8.76% |
Earnings, dividends, cash flow and book value per share, sourced from Morningstar.
| EPS excluding extraordinary items - most recent fiscal year | 6.790 |
| EPS excluding extraordinary items - trailing 12 month | 7.810 |
| EPS Normalized - most recent fiscal year | 7.290 |
| Revenue/share - most recent fiscal year | 42.285 |
| Revenue/share - trailing 12 month | 46.046 |
| Book value per share - most recent fiscal year | 44.085 |
| Book value per share - most recent quarter | 42.474 |
| Book value (tangible) per share - most recent fiscal year | 42.451 |
| Book value (tangible) per share - most recent quarter | 40.839 |
| Cash per share - most recent fiscal year | 10.984 |
| Cash per share - most recent quarter | 6.190 |
| Cash Flow per share - most recent fiscal year | 9.285 |
| Cash Flow per share - trailing 12 month | 10.620 |
| Dividend per share - most recent fiscal year | 0.860 |
| Dividends per share - trailing 12 month | 0.880 |
| EBITD per share - trailing 12 month | 11.914 |
| EPS Basic excluding extraordinary items - most recent fiscal year | 6.830 |
| EPS Basic excluding extraordinary items - trailing 12 month | 7.870 |
| EPS including extraordinary items - most recent fiscal year | 6.830 |
| EPS including extraordinary items - trailing 12 month | 7.870 |
| Free Cash Flow per share - trailing 12 month | 7.502 |
Valuation multiples such as P/E, price to sales, price to book and enterprise value ratios, sourced from Morningstar.
| P/E excluding extraordinary items, most recent fiscal year | 50.38 |
| P/E Normalized, most recent fiscal year | 46.29 |
| Price to sales - most recent fiscal year | 8.55 |
| Price to Tangible Book - most fiscal year | 9.63 |
| Price to Free Cash Flow per Share - most recent fiscal year | 52.45 |
| Price to Cash Flow per share - trailing 12 month | 37.05 |
| Price to Book - most recent fiscal year | 9.26 |
| P/E excluding extraordinary items high, trailing 12 months | 50.38 |
| P/E excluding extraordinary items low, trailing 12 months | 34.03 |
| Net Debt, LFI | -123.70 |
| Net Debt, LFY | -470.20 |
| Dividend Yield - 5 Year Average | 0.25% |
| Dividend Yield - indicated annual dividend divided by closing price | 0.23% |
| Current Dividend Yield - Common Stock Primary Issue, LTM | 0.22% |
Cash flow, liquidity and leverage measures, sourced from Morningstar.
| Free Cash Flow - most recent fiscal year | 389.10 |
| LT debt/equity - most recent fiscal year | 9.40% |
| Payout ratio - most recent fiscal year | 12.67% |
| Total debt/total equity - most recent fiscal year | 10.11% |
| LT debt/equity - most recent quarter | 9.74% |
| Total debt/total equity - most recent quarter | 10.44% |
| Free Cash Flow - trailing 12 month | 542.00 |
| Payout ratio - trailing 12 month | 8.45% |
Key income statement lines for the most recent fiscal year, in millions, sourced from Morningstar.
| Revenue - most recent fiscal year | 3,074.10 |
| Revenue - trailing 12 month | 3,326.80 |
| EBITD - most recent fiscal year | 755.30 |
| EBITD - trailing 12 month | 860.80 |
| Earnings before taxes - most recent fiscal year | 600.90 |
| Earnings before taxes - trailing 12 month | 693.60 |
| Net Income available to common - most recent fiscal year | 493.70 |
| Net Income available to common - trailing 12 months | 564.90 |
| Earnings before taxes Normalized - most recent fiscal year | 673.40 |
| Net Income Available to Common, Normalized - most recent fiscal year | 529.90 |
| Earnings per Share, Normalized, Excluding Extraordinary Items, Avg. Diluted Shares Outstanding, TTM | 8.50 |
Profitability margins for the most recent fiscal year, sourced from Morningstar.
| Net Profit Margin % - 1st historical fiscal year | 16.06% |
| Net Profit Margin % - trailing 12 month | 16.98% |
| Operating margin - 1st historical fiscal year | 20.69% |
| Operating margin - trailing 12 month | 21.72% |
| Pretax margin - trailing 12 month | 20.85% |
| Pretax margin - 1st historical fiscal year | 19.55% |
| Operating Margin - 5 year average | 23.66% |
| Pretax Margin - 5 year average | 22.69% |
| Free Operating Cash Flow/Revenue, 5 Year Average | 14.22% |
| Free Operating Cash Flow/Revenue, TTM | 16.29% |
| Net Profit Margin - 5 year average | 19.37% |
Returns on average assets and equity for the fiscal year, the trailing 12 months and as 5 year averages, and net income and revenue per employee in whole currency, sourced from Morningstar.
| Return on average assets - most recent fiscal year | 12.60% |
| Return on average assets - trailing 12 month | 13.77% |
| Return on average equity - most recent fiscal year | 17.00% |
| Return on average equity - trailing 12 month | 18.66% |
| Return on average assets - 5 year average | 16.08% |
| Return on average equity - 5 year average | 22.15% |
| Net Income/employee - most recent fiscal year | 45,712.96 |
| Revenue/employee - most recent fiscal year | 284,638.89 |
Growth in revenue, earnings, dividends and book value over recent periods, sourced from Morningstar.
| Revenue growth rate, 5 year | 7.44% |
| EPS growth rate, 5 year | 8.24% |
| Growth rate% - dividend, 3 year | 5.20% |
| Revenue/share (5 yr growth) | 8.34% |
| Growth rate% - Revenue, 3 year | 2.12% |
| Growth rate% - EPS, 3 year | -4.23% |
| Book value per share growth rate, 5 year | 11.96% |
| Capital Spending growth rate, 5 year | 10.39% |
| Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year CAGR | 7.87% |
Displays analyst’s forecasts for key measures. The estimates can be expanded to see the spread of the calls. Full lines = reported, and dotted lines are forward estimates. Click a measure to add or remove it from the chart, sourced from Morningstar.
Financial forecast (USD, millions except per share)
| Actuals | Estimates | |||||||
| 2025 | 2026 | 2027 | 2028 | 2029 | ||||
| Estimate breakdown | ||||||||
Financial metrics can be plotted on the graph to see trends. Multiple metrics from multiple statements can be plotted against each other, sourced from Morningstar.
Financials (USD, millions)
| Period end: | DEC 21 | DEC 22 | DEC 23 | DEC 24 | DEC 25 |
| Fiscal year: | 2021 | 2022 | 2023 | 2024 | 2025 |
| Period length: | 12 months | 12 months | 12 months | 12 months | 12 months |
Displays all company announcements released by the company to the exchange, sourced from Morningstar.
Announcements
Announcements are available for ASX-listed companies only.
Opinion
No opinions for this company yet.
Action
No actions for this company yet.
Business Summary
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
Relevant suggested news and content from the site
Video
WATCH
Webinar Recording: Are commodities entering a Supercycle?
Recorded Wednesday 24th June @ 12.30pm
Podcast
LISTEN
Thursday 11th September – Dow off -220pts, SPI off -20pts
Daily Podcast Direct from the Desk
Video
WATCH
Buy Hold Sell: The 6 income stocks readers love, plus 2 expert ideas
Recorded 10th June 2026
Podcast
LISTEN
Wednesday 10th September – Dow up +196pts, SPI down -4pts
Daily Podcast Direct from the Desk
